Compared to idarubicin, GO when added to FLAG based frontline induction/consolidation regimen results in better early molecular responses and improved relapse free survival in CBF AML. Click and hear Gautam Borthakur present the new data.  

In this MEDtalk John F. Seymour present the key data from MURANO study. Venetoclax (Ven) is a highly selective oral inhibitor of BCL2, a key regulator of the intrinsic apoptotic pathway, which is constitutively overexpressed in CLL. Efficacy and safety of VenR given for a fixed duration in R/R CLL was evaluated in the randomized Phase III MURANO study compared with standard bendamustine + rituximab (BR). With all patients off treatment and 3 years’ median follow-up, continued substantial benefit was observed with VenR, with PFS and OS superior to BR. There were no new safety signals; most pts were able to complete treatment. The rate of CLL progression in the first 12 mo after Ven completion was modest (13%), supporting the feasibility and safety of a time-limited VenR duration.  

Both the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) and the CD3-CD19 bispecific T-cell engager blinatumomab have single-agent activity in relapsed or refractory acute lymphoblastic leukemia (ALL). We previously reported the promising efficacy and survival of INO in combination with low-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL. In this MEDtalk Nicholas J. Short tell how toimprove these outcomes by adding blinatumomab to this regimen. The study show, that mini-hyper-CVD + INO ± blinatumomab, is safe and effective in elderly pts with newly diagnosed Ph-negative ALL, with an overall response rate of 98% and 3-year OS rate of 54%.  

MEST SETE MEDtalks

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)   Se hele webinar

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

<script src="https://fast.wistia.com/embed/medias/8r1j245h32.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8r1j245h32 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8r1j245h32/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Should all eligible patients with multiple myeloma have tandem transplant? (3:3)&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/should-all-eligible-patients-with-multiple-myeloma-have-tandem-transplant-33/'>Se hele webinar
Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

Discussion of established combinations and new combinations in multiple myeloma (2:3)

<script src="https://fast.wistia.com/embed/medias/8r1j245h32.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8r1j245h32 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8r1j245h32/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Discussion of established combinations and new combinations in multiple myeloma (2:3)&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/discussion-of-established-combinations-and-new-combinations-in-multiple-myeloma-23/'>Se hele webinar
Discussion of established combinations and new combinations in multiple myeloma (2:3)

Smouldering myeloma and high risk patients – a close look at GEM-CESAR and CENTAURUS studies (1:3)

<script src="https://fast.wistia.com/embed/medias/8r1j245h32.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8r1j245h32 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8r1j245h32/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/smouldering-myeloma-and-high-risk-patients-a-close-look-at-gem-cesar-and-centaurus-studies-13/'>Se hele webinar
Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Real-world evidence from the Belgian registry shows that ponatinib has a favorable efficacy and safety profile in, and supports its use in CML and Ph+ ALL patients who are resistant or intolerant to previous therapies or those with the T315I mutation. Deep molecular responses were obtained in the majority of patients. No new safety signals emerged with ponatinib treatment than those previously reported.  

In this MEDtalk Guy Young present data from HAVEN 2 - the largest prospective study in pediatric PwHA with inhibitors to date. HAVEN 2 demonstrates that emicizumab prophylaxis is well tolerated and can prevent or substantially reduce bleeds in this population. Meaningful efficacy and PK were maintained with less frequent dosing, with no new safety signals, suggesting the potential for reduced treatment burden in the pediatric population. Additionally, the large number of CVAD removals suggests that prophylactic emicizumab may offer a new and effective standard of care for hemophilia that is also more convenient and less invasive, and may offer the potential for flexible treatment regimens based on patient needs.  

In this MEDtalk John Gribben, Professor, MD DSc, Barts Cancer Institute, University of London, present the key data from MURANO study about treatment of relapsed/Refractory CLL.  

#Senaste Tidskrifter

Onkologi / Hematologi

NR. 4 • september 2018
Årgång 2
  • EHA 2018
  • Prostatacancer
  • Bröstcancerrisk

ASH 2018

EHA 2018

#

Hematologi / Onkologi

Vladimir Lazarevic,

Vladimir Lazarevic,
överläkare

Hareth Nahi

Hareth Nahi
med.dr, fil.dr